In addition to our innovative drug products based on our proprietary delivery technology, we have a portfolio of generic product candidates with favorable commercial agreements.
In Market
acyclovir cream, 5%
(RLD: ZOVIRAX®)
Sales as of
January 2019
Pending
ivermectin cream, 1%
(RLD: SOOLANTRA®)
Tentative Approval
as of January 2019
halobetasol propionate lotion, 0.01%
(RLD: BRYHALI®)
Filed Paragraph IV
Certification January 2020
halobetasol propionate and tazarotene lotion, 0.01%/0.045%
(RLD: DUOBRII®)
Filed Paragraph IV
Certification June 2020
5-fluorouracil cream, 5%
(RLD: EFUDEX®)
Bioequivalence
Study Completed
All trademarks are the properties of their prospective owners.